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Abstract Cachexia affects up to two thirds of all cancer
patients and is a significant cause of morbidity and
mortality. It is a complex metabolic syndrome associated
with the underlying illness and characterized by loss of
skeletal muscle tissue with or without loss of fat mass.
Cachexia’s other prominent clinical symptoms include
anorexia, systemic inflammation, pediatric growth failure,
and hypogonadism. The relationship between the symp-
toms of cancer cachexia and the underlying illness is
unclear, and there is an urgent need for a better
understanding of the pathophysiology of this syndrome.
Normal Zn metabolism is often disrupted in cancer
patients, but the possible effects of systemic Zn dysho-
meostasis in cachexia have not been investigated. We
propose that the acute phase response can mediate Zn
redistribution and accumulation in skeletal muscle tissue
and contribute to the activation of the ubiquitin–protea-
some pathway that regulates protein catabolism. This
chronic redistribution deprives Zn from other tissues and
organs and compromises critical physiological functions
in the body. The cardinal symptoms of Zn deficiency are
anorexia, systemic inflammation, growth failure in
children, and hypogonadism. These symptoms also
prominently characterize cancer cachexia suggesting that
the role of systemic Zn dyshomeostasis in cachexia
should be investigated.
Keywords Cachexia muscle wasting.Zinc.Systemic Zn
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1 Introduction
Cachexia affects up to two thirds of all cancer patients
and is directly responsible for one fifth of all cancer-
related deaths [1]. Muscle wasting is one of the most
devastating, complex, and enigmatic aspects of cancer, but
it is also common in other conditions such as chronic heart
failure [2], chronic obstructive pulmonary disease [3],
chronic kidney disease [4], chronic inflammation [5],
severe trauma [6], AIDS [7], and sepsis [8]. The 2008
Cachexia Consensus Conference defined cachexia as “a
complex metabolic syndrome associated with underlying
illness and characterized by loss of muscle with or without
loss of fat mass.” Other prominent clinical features of
cachexia include anorexia, systemic inflammation, pediat-
ric growth failure, and hypogonadism [9]. It is unclear
how these symptoms are related to each other or to the
underlying illness, and as Lainscak and colleagues
recently noted, there is an urgent need for effective
therapies and a precise definition of this common and
deadly syndrome [10].
We propose that systemic Zn dyshomeostasis is a
salient characteristic of cancer cachexia, and that Zn
redistribution is mediated by the acute phase response
(APR) as a host defense mechanism in response to
infection, inflammation, trauma, or cancer. We hypothe-
size that chronic APR can induce significant Zn
accumulation in skeletal muscle tissue resulting in ubiqui-
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functional systemic Zn deficiency associated with anorexia,
inflammation, growth failure, and hypogonadism.
Zn is a critical trace element that has a broad range of vital
catalytic and structural functions in all eukaryotic cells and
higher organisms, and it is of exceptional biologic importance
for humans [11]. As Maret points out, “Zn ions are essential
for all forms of life. In humans, they have catalytic and
structural functions in an estimated 3,000 zinc proteins” [12].
Zn homeostasis is often disturbed during cancer, and in
certain malignancies Zn uptake appears to be an index of
tumor viability [13]. Zn can also upregulate telomerase
activity that is associated with the unlimited proliferation of
cancer cells [14, 15]. However, Murakami and Hirano note
that while tumors need Zn to survive and grow, “excess Zn
may induce tumor cell apoptosis, although the sensitivities of
the different types of tumors are likely to vary” [16]. Low Zn
levels have been reported in cancer patients [17–22], but
we are aware of only one clinical study that specifically
examined the link between serum Zn levels and cancer-
induced muscle wasting [23]. In 1989, Westin and
colleagues showed in a small pilot study with 6 patients that
cachecticsubjectswithheadandneckcancerhadsignificantly
lower serum Zn levels compared to controls (p<0.025). The
results should be viewed with caution due to the small size of
the cohort and the fact that the patients were alcoholics.
Alcohol abuse has been associated with abnormal Zn
metabolism. It is important to note that while Zn is commonly
measured from serum, normal levels can be found in patients
suffering from Zn dyshomeostasis due to Zn released from
catabolic muscles, hemolysis, protein binding, hormone-
mediated redistribution, and postprandial effects [23, 24].
Future studies should consider an alternative method
suggested by Prasad and colleagues for determining Zn
status in humans that is not affected by these processes [25].
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THE ZINC-CACHEXIA HYPOTHESIS: OVERVIEW
There are other important clinical mechanisms that can
contribute to systemic Zn dyshomeostasis in cancer
patients. These include low dietary intake of Zn, hypo-
albuminemia, and fecal losses of Zn. The adult body
contains 2–3 g of Zn [26], of which 57% is found in
skeletal muscle and 29% in bone [27]. However, there is no
functional reserve or store for Zn. The body uses a small
rapidly exchangeable pool of Zn which is dependent on
constant nutritional replenishment. The recommended daily
allowance (RDA) for Zn is 15 mg [28], and low daily
intake of Zn rich food stuffs such as shellfish, beef, lamb,
veal, and poultry [29] can contribute to Zn deficiency in
cancer patients. The majority (75–85%) of plasma Zn is
bound to serum albumin [30], and hypoalbuminemia can
compromise Zn transport. Finally, fecal losses of Zn due to
gastrointestinal surgery associated with cancer can contrib-
ute to low Zn levels [31].
2 APR and Zn redistribution
We hypothesize that systemic Zn redistribution and
dyshomeostasis play a central role in cancer cachexia.
However, Zn metabolism is vital for human health and is
normally tightly regulated. There is no systemic store for
Zn [32], yet the body seems to be able to accommodate
tenfold changes in Zn intake by adjusting the rate of
absorption and excretion of the metal [27]. Considering
how vigilantly physiological Zn homeostasis is main-
tained, we investigated if there is an identifiable mecha-
nism that can initiate and sustain the redistribution of Zn
in pathological situations.
APR is a host defense mechanism triggered in
response to trauma, inflammation, infection, and cancer.
Gabay and Kushner explain that “al a r g en u m b e ro f
changes, distant from the site or sites of inflammation
and involving many organ systems, may accompany
inflammation [and] these systemic changes [are] referred
to as the acute phase response, even though they
accompany both acute and chronic inflammation” [33].
APR seems to play an important role in cancer cachexia
and as Stephens, Skipworth, and Fearon note, “at the time
of diagnosis, around half of all cancer patients will
demonstrate an APR” [1]. The proportion of patients with
APR increases with the progression of the disease, and in
certain malignancies, the presence of APR is a significant
predictor of survival [34].
One of the main functions of APR is the orchestrated
acceleration of hepatic production of specific plasma
proteins used during the defense response. To achieve this
increased rate of protein production, APR initiates the
hepatic amino acid uptake and the large increase in the
synthesis of acute phase proteins by the liver [35]. The liver
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amino acids at a significantly (p<0.025) higher rate
compared to healthy controls [36]. The persistent hepatic
synthesis of acute phase reactants may represent a nutri-
tional sink that sucks amino acids mobilized from skeletal
muscle tissue that is aggressively broken down during
APR. Indeed, 2.6 g of muscle protein must be catabolized
to produce 1 g of fibrinogen [1], one of the most important
acute phase proteins [37]. The correlation between muscle
wasting and increased hepatic protein synthesis is known,
but the mechanism behind APR-mediated protein catabo-
lism in skeletal muscle is poorly understood.
The redistribution of systemic Zn and hypozincemia are
prominent characteristics of APR [33, 35, 38]. Clinical data
indicate that APR-induced hypozincemia is in part due to
internal Zn redistribution [39, 40], the liver being a major
target [41]. However, Zn can also be redistributed into
skeletal muscle during APR. A rat model of chronic heart
failure that uses aldosterone to induce a persistent APR
showed Zn
65 uptake not only in the liver, but also in
uninjured skeletal muscle where Zn
65 increased nearly
twofold after 1 week of aldosterone administration and
remained 50% higher than controls at week 4 [42].
The pro-inflammatory cytokines, in particular tumor
necrosis factor-α (TNF-α), interleukin-1 (IL-1), and
interleukin-6 (IL-6) that are central to the induction of the
APR [1], significantly reduce systemic Zn levels. The
administration of TNF-α (p<0.01; [43]), IL-6 (p<0.001;
[44]), and lipopolysaccharide (LPS; p<0.0001; [39]) results
in the significant decrease of serum Zn levels. The chronic
administration of IL-1 to rats resulted in significantly
reduced plasma Zn levels (<70 μg/dl vs. >110 μg/dl, p<
0.01), severely diminished appetite (p<0.0001), increased
protein breakdown and decreased synthesis (p<0.05), and
over a tenfold increase in IL-6 plasma levels (p<0.001;
[45]). IL-6 significantly (p<0.01) upregulates the Zrt/IRT-
like protein (ZIP) 14 Zn influx transporter that has a
central role in inducing hypozincemia during APR [35].
The Zn transporters are divided into the ZIP influx and the
Zn-transporter efflux transporter groups [46]. They move
Zn into and out of cells and organelles and are responsible for
Zn redistribution in pathological situations such as inflamma-
tion and cancer [47]. Key APR factors directly regulate Zn
homeostasis, and chronic APR can lead to perpetual
systemic Zn redistribution. These results also help to explain
why cancer patients, who commonly demonstrate chronic
APR, also suffer from systemic Zn dyshomeostasis.
3 Zn accumulation in muscle tissue
We suggest that systemic Zn dyshomeostasis observed in
cancer is in part due to the accumulation of Zn in skeletal
muscletissuethatconstitutes∼40% ofhumanbodymass(BM).
Malignant growth disturbs the Zn metabolism in the body [16],
but we know of only two pre-clinical studies that specifically
examined the relationship between cancer-induced muscle
wasting and Zn accumulation in muscle tissue. A 1987
fibrosarcoma study with rats showed that Zn is significantly
accumulated into cachexic skeletal muscle tissue (p<0.05;
[48]). Zn levels in the tumor tissue doubled in the same 12-
day period. We recently examined the role of Zn in the
cachexia-inducing murine adenocarcinoma-16 (MAC-16)
model and showed that Zn levels in skeletal muscle tissue
correlate with muscle wasting [49]. The Zn concentration in
the gastrocnemius muscle of mice with more than 20% weight
loss was twice as high as that in controls (p<0.05). The
extracellular Zn chelating compound D-myo-inositol 1,2,6-
triphosphate (Alpha trinositol, AT; Bioneris Ab; [50]), a
polyanionic isomer of myo-inositol phosphate that forms a
mononuclear 1:1 complex with Zn and binds the ion to
phosphates P1 and P6 in its inositol ring structure [51],
reduced Zn accumulation (p<0.05) in skeletal muscle tissue
while significantly attenuating muscle atrophy (p<0.001;
[49]). We have previously shown that AT attenuates both the
loss of lean body mass (p<0.001) and tumor growth (p<
0.01) in the MAC-16 model. The anti-cachexic effect of AT
was not dependent on tumor suppression. [52]. Also another
metal chelator, curcumin (diferuloylmethane), that binds Zn
through its beta-diketone group and forms a mononuclear
(1:1) complex with Zn [53], attenuates weight loss (p<0.05)
in the MAC-16 model [54].
A 1986 Lewis Lung Carcinoma (LLC) study showed
that 21 days after tumor implantation Zn concentration in
murine skeletal muscle tissue had doubled compared to the
controls (p<0.01). The study did not measure muscle
wasting [55], but LLC is known to cause cachexia and is
commonly used as an animal model for the syndrome [56–
58]. Interestingly, a 1987 study on hamsters with muscular
dystrophy showed an 82% increase in the skeletal muscle
Zn levels compared to controls (p<0.001; [59]). A recent
study in mice with dystrophic muscle wasting reported
similar results [60].
A recent clinical pilot study with 26 cancer cachexia
patients showed that Zn progressively and significantly (p<
0.01) accumulates in the skeletal muscle tissue of cachexic
patients. In patients with more than 9.5% weight loss, the Zn
concentration in skeletal muscle tissue more than doubled
compared to healthy controls (Siren et al., unpublished
results). To our knowledge this is the first clinical measure-
ment of Zn concentrations in cachexic skeletal muscle tissue.
Considering that in healthy individuals, approximately 60%
of total body Zn is found in skeletal muscle tissue [27], that
constitutes ~40 % of total BM, the doubling of Zn levels in
cachexic muscle indicates that these patients suffer from
severe systemic Zn dyshomeostasis.
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andthe clinicalusefulnessofthistrace elementasa diagnostic
biomarker for muscle wasting should be investigated.
4 Zn and the ubiquitin–proteasome pathway
It is unclear if Zn accumulation in cachexic skeletal muscle
is a cause or an effect of protein catabolism. However, the
fact that Zn chelators can significantly attenuate muscle
wasting in vivo and also attenuate both increased protein
degradation and decreased protein synthesis induced by
diverse cachexic factors in vitro suggests that the ion may
be a causative factor in the catabolic process.
In cachexia, increased protein degradation and decreased
protein synthesis occur simultaneously and result in muscle
wasting. The activation of the ubiquitin–proteasome pathway
seems to be essential for protein catabolism [61–63] and has
been implicated in a variety of pathological conditions [64].
According to Tisdale, “studies in animal models of cancer
cachexia, as well as in cancer patients, suggest that the
ubiquitin–proteasome pathway plays the predominant role in
the degradation of myofibrillar proteins, particularly in
patients with a weight loss of >10%” [65]. Double-stranded
RNA-dependent protein kinase (PKR) seems to play an
important in role the activation of the ubiquitin–proteasome
pathway. Phosphorylation of PKR leads to the induction of
eukaryotic initiation factor 2α (eIF2α) phosphorylation
resulting in depressed protein synthesis. PKR also activates
IκB kinase, leading to the degradation of the inhibitors IκBa
and IκBb and the concomitant release of nuclear factor-κB
(NF-κB) that is a central regulator of protein degradation [66].
Eley and Tisdale conclude that the “activation of PKR may
provide the link between the inhibition of protein synthesis
and induction of muscle protein degradation, leading to
muscle atrophy in response to diverse cellular stress in a
range of conditions in addition to cancer cachexia, including
HIV-AIDS, sepsis, burns, and weightlessness” [67].
ATisanextracellularZn chelatorthateffectively attenuates
both the increased protein degradation and decreased protein
synthesis induced by TNF-α,T N F - α+interferon-gamma,
LPS, proteolysis-inducing factor (PIF), and angiotensin II
(Ang II; all p<0.001; [68]). Tisdale notes that the activation
of PKR is thought to be critical for both the depression
protein synthesis and the increase in protein degradation, and
that AT likely inhibits a common step leading to the
activation of PKR. The effect of AT on protein degradation
is accompanied by the attenuation of the increasedexpression
and activity of the ubiquitin–proteasome pathway. AT
completely attenuated the activation of PIF-induced phos-
phorylation of both PKR and eIF2α and the nuclear
accumulation of NF-κB( a l lp<0.001). AT also inhibited
the activation of caspase-3 and -8 (p<0.001), which are
thought to lead to the activation of PKR. The ability of
increasing concentrations Zn to reverse the attenuation by AT
of the increased activity of the ubiquitin–proteasome pathway
induced by PIF and Ang II, as well as the depression of
protein synthesis induced by PIF (all p<0.001), indicates that
Zn may be involved in the signaling process.
5 Effects of systemic Zn dyshomeostasis
We argue that chronic functional Zn deficiency in specific
tissues and organs contributes to the salient clinical
symptoms of cancer cachexia such as anorexia, systemic
inflammation, pediatric growth failure, and hypogonadism.
Zn dyshomeostasis associated with cancer may have serious
implications for systemic Zn metabolism. As King and
colleagues note, “because plasma must provide Zn to all the
tissues, maintaining relatively constant plasma Zn concen-
trations is essential to sustaining normal function and health”
[27]. PhysiologicalsignsofZndepletionarenotevidentuntila
dropinplasmaZnconcentrationoccurs,butclinicalsymptoms
manifest rapidly thereafter. Zn deficiency has been studied for
nine decades and is characterized by symptoms that are
strikingly similar to those commonly found in cachexia.
Against this background, it is indeed surprising that the
possible link between systemic Zn dyshomeostasis and cancer
cachexia has not been investigated.
However, nutritional factors such as leucine and other
branched chain amino acids, arginine, glutamine, polyun-
saturated fatty acids [69], creatine [70], and cystine [71]
have been studied in relation to cancer cachexia. These
factors have limited metabolic functions, and they cannot
account for the severe and multifaceted symptoms that
saliently characterize cachexia.
6 Anorexia in cachexia
Anorexia, broadly defined as the loss of appetite or desire
to eat, is common in cancer cachexia patients. However,
anorexia appears to be a distinct syndrome as it does not
cause loss of lean body mass by itself [72]. The relationship
between cachexia and anorexia is unclear, but it has been
argued that cancer anorexia may result from the signaling
defects of orexigenic factors such as neuropeptide Y (NPY;
[65]). There is a demonstrated decrease in hypothalamic
NPY immunostaining in tumor-bearing rats [73], and in
anorexic cancer patients, the mean NPY serum levels are
significantly (p<0.004) lower compared with healthy
controls [74]. Zn deficiency is thought to induce anorexia
by impairing the release of NPY from the terminals in the
paraventicular nucleus of the hypothalamus that is required
for receptor activation [75].
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many animal species [76, 77]. Chesters and Quarterman
observed already 40 years ago that “a fall in food intake is
highly characteristic of Zn deficiency” [78]. Young rats are
very responsive to a Zn-deficient diet and exhibit decreased
food intake within 3–5 days of Zn deprivation. Decreased
appetite is the first visible sign of Zn deficiency, and it
generally occurs in advance of other symptoms [79].
The correlation between anorexia and low systemic Zn
levels has also been extensively studied in humans. Patients
with eating disorders may develop Zn deficiency for a
variety of reasons, such as low dietary intake of Zn,
impaired Zn absorption, vomiting, diarrhea, and binging on
low Zn foods [80]. Anorexia patients may also suffer from
diminished absorption of dietary Zn [81]. A study with 30
hospitalized anorexic patients who had lost 34% of the
height/age adjusted weight, found that the mean plasma Zn
level was considerably lower compared to healthy controls
(p<0.01). Eight patients had plasma Zn levels below 60 μg/
dl [82]. Another clinical study with 24 anorexic patients
showed that 54% had biochemical evidence of Zn defi-
ciency [83]. In several open trials, Zn supplementation has
improved weight gain in anorexia patients [84–86]. In a
randomized, double-blinded clinical study, the rate of
increase in the body mass index (BMI) of the Zn
supplemented group was twice that of the placebo group
(p>0.03) [87]. Still, the role of Zn deficiency in the onset
and progression of anorexia is both unappreciated and
underestimated [79]. Several authors advocate the use of Zn
supplementation as a cheap, effective and safe treatment for
anorexia [88–90].
We compared the serum Znlevelsinanorexiapatientswith
those of cancer patients to investigate the possible role of Zn
dyshomeostasis in cancer-induced anorexia. Three clinical
studieswithanorexiapatientswholostbetween15%and50%
of their original body weight reported mean serum Zn levels
between 71.9 μg/dl and 73.9 μg/dl [24, 82, 91]. Patients with
a variety of malignancies (carcinoma of the bronchus, lung,
breast prostate, bladder, cervix, gallbladder and mouth)
reported mean serum Zn levels between 59.6 μg/dl and
77.2 μg/dl. The corresponding range in healthy controls was
95.5–99.3 μg/dl [18, 92, 93]. These results indicate that cancer
patients can have serum Zn levels as low as or lower than
patients with advanced anorexia.
We know of only one clinical study that specifically
examined the relationship between cancer cachexia-induced
anorexia and serum Zn levels [94]. The average weight of 10
small cell lung carcinoma patients declined from 81.7 to
74.1 kg during a 7 month period. The patients suffered from
diminished appetite, and their mean caloric intake was 72%
of the RDA. The mean serum Zn concentration in the study
group was 71 μg/dl. The authors of the 1986 study
characterize this level as low but normal, and conclude that
Zn does not appear to be an anorexigenic factor. We suggest
that this conclusion is incorrect, because studies in non-
cancer anorexia patients show that anorexia is associated
with Zn serum levels below 75 μg/dl. Cancer cachexia
patients with anorexia may suffer from functional systemic
Zn deficiency, and Zn should be evaluated as a possible
clinical biomarker in these patients.
7 Systemic inflammation in cachexia
Immunodeficiency is associated with many types of
malignancies, including head and neck, lung, esophagus
and breast cancer, but the underlying mechanisms are
poorly understood [95]. The correlation between systemic
inflammation and cancer cachexia was first demonstrated
by Simons and colleagues in 1999 [96]. Recently, Fearon
noted that systemic inflammation, defined as C-reactive
protein >10 mg/l, is a key feature of cancer cachexia [97].
The correlation between chronic systemic inflammation and
progressive loss of lean body mass has been observed in
several clinical studies [98].
Altered Zn metabolism may contribute to systemic
inflammation observed in cancer cachexia because Zn
homeostasis is critical for efficient immune function [99].
Haase and Rink observe that “zinc is essential for the
immune system, and zinc deficiency affects multiple
aspects of innate and adaptive immunity” [100]. Already
mild forms of Zn deficiency adversely affect immunity
[101], and Zn deficiency is constantly observed in clinical
cases of chronic systemic inflammation [102]. Mouse
models have demonstrated that 30 days of suboptimal
intake of Zn can lead to 30–80% losses in the host’s
immune defense capacity [103]. Patients with diminished
systemic Zn levels show a diminished immune response
and a far greater susceptibility to infection. Zn supplemen-
tation reduces both spontaneous inflammatory activity (p<
0.001) and defects in the termination of inflammatory
activity in elderly subjects [104]. The results from the past
three decades indicate that Zn deficiency diminishes
antibody- and cell-mediated immune responses in both
humans and animals [105–107].
Zn has a broad impact on key immunity mediators, such
as enzymes, thymic peptides, and cytokines, and regulates
lymphoid cell activation, proliferation, and apoptosis [108].
The activity of practically all immune cells is modulated by
Zn in vitro and in vivo, and Zn affects the expression of
hundreds of genes in immune cells. Inflammation disrupts
Zn homeostasis on both a systemic and cell level, and Zn
deficiency that is a secondary characteristic of many
diseases may aggravate the underlying condition [109].
The integrity of the human immune system can be severely
impaired by functional Zn deficiency, and chronic Zn
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inflammation observed in cachexia patients.
8 Growth failure in cachexia
Growth failure is commonly observed in pediatric patients
suffering from cancer cachexia [9, 110]. The specific
reasons for cancer associated growth failure are unknown,
but it has been suggested that the reasons are multifactorial
and include increased metabolic rate and lipolysis, de-
creased nutrient intake, and changes in carbohydrate and
protein metabolism [111, 112]. The metabolic changes
associated with cancer cachexia are complex, and it is
unlikely that one factor by itself could explain impaired
growth in pediatric patients. However, we suggest that Zn
redistribution and dyshomeostasis may contribute to growth
failure in cachexic children.
Zn is essential to the function of a large number of
macromolecules and for over 300 enzymic reactions [113],
and as MacDonald notes, “the inhibition of growth is the
cardinal symptom of zinc deficiency” [114]. Raulin
demonstrated in 1869 that Zn is necessary for the growth
of the fungus Aspergillus niger [115]. Since then, its critical
role in the normal development of higher plants [116],
animals [117–119], and humans [120] has been established.
Zn deficiency adversely and seriously affects growth in
animals and humans [121, 122]. Reduced energy intake is
not the limiting factor in growth because force feeding a
Zn-inadequate diet to animals fails to maintain growth
[114]. Zn deficiency is often the result of insufficient
dietary intake or poor absorption through the digestive tract.
Not surprisingly, growth failure caused by Zn deficiency is
recognized as a serious nutritional health issue in many
developing countries [123].
Zn deficiency results in retarded growth in infants and
children [124–126]. Already moderate Zn deficiency causes
growth retardation and delayed puberty in adolescents
[121]. Prenatal Zn supplementation correlates significantly
(p<0.001) with infant weight [127]. Children who suffered
from stunted growth and who received Zn supplementation
significantly (p<0.001) increased in both height and weight
compared to the placebo group [128]. Pediatric geophagia
patients who suffered from marked growth failure had
subnormal serum Zn levels compared to controls (73.9 μg/
dl vs. 110.5 μg/dl; p<0.001). The growth failure was
significantly attenuated by Zn supplementation [129].
Interestingly, the mean serum Zn levels in the geophagic
patients were comparable to those of patients with serious
anorexia (71.9–73.9 μg/dl) and advanced cancer (59.6–
77.2 μ/dl).
We propose that Zn dyshomeostasis may contribute to
the growth failure in pediatric cancer patients. If functional
Zn deficiency is verified as a causative factor in cachexic
growth failure, it could provide clinicians with a novel
biomarker and improve pediatric care.
9 Hypogonadism in cachexia
Hypogonadism refers to a defect of the gonads that results
in the underproduction of testosterone and is common in
cancer patients, especially in those suffering from weight
loss. A recent clinical study noted that “hypogonadism is a
frequent condition in patients with advanced, incurable
cancer and is associated with negative mood, fatigue, and
symptoms related to anorexia/cachexia” [130]. Chlebowski
and Heber studied 44 patients with lung cancer, adenocarci-
noma of the colon and rectum, and prostate carcinoma with
proven metastatic spreads [131]. The mean ideal body weight
of patients with low testosterone and low or normal
luteinizing hormone was significantly lower (p<0.05) than
in patients with normal testosterone levels. The authors
conclude that “hypogonadism is a relatively common
biochemical abnormality in men with cancer, particularly in
patients experiencing weight loss.”
The metabolic link between hypogonadism and cachexia
is unresolved, but the critical role of Zn in gonad function
and steroidogenesis is well known. Zn is essential for
spermatogenesis and testosterone steroidogenesis [132],
and hypogonadism is a classic symptom of Zn deficiency
[133]. The first study linking Zn and testosterone metabo-
lism by the prostate gland was published in 1971 [134].
Karaca and colleagues succinctly note that “hypogonadism
is a major manifestation of Zn deficiency in both humans
and animals” [135].
Several possible molecular mechanisms linking Zn and
hypogonadism have been proposed. Hypogonadism asso-
ciated with Zn deficiency seems to result from changes in
testicular steroidogenesis or indirectly from Leydig cell
failure [136]. A study with young rams showed that Zn
deficiency completely blocked testicular growth [137]. The
Zn-specific effect on gonad function is localized within the
testis where it reduces the capacity to produce testosterone,
leading to low intratesticular concentrations of testosterone,
a critical factor for the growth, development, and function
of the seminiferous tubules. This mechanism seems to be
related to the biochemical disruption of Leydig cell
function.
Zn can directly modulate serum testosterone levels, and
in rats, Zn supplementation results in a considerable
increase in testosterone levels (p<0.05; [138]). In the
clinical study on healthy males, testosterone concentrations
declined significantly (p=0.005) after 20 weeks on a Zn-
deficient diet serum [139]. It is known that diminished
levels of anabolic hormones, e.g., testosterone, can lead to
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dyshomeostasis could exacerbate muscle wasting also
through a secondary mechanism. Cancer cachexia patients
with functional Zn deficiency may suffer from impaired
steroidogenesis and gonad activity since Zn is critical for
both functions.
10 Conclusion
Cachexia is a complex metabolic syndrome, and the debate
regarding its definition is ongoing. In this paper, we have
examined the link between cancer cachexia and systemic Zn
redistribution. Zn dyshomeostasis has been associated with
malignant growth, but the pathophysiological consequences
of chronic Zn redistribution during cancer cachexia have been
ignored. We suggest that Zn dyshomeostasis is associated
with the salient symptoms of cachexia such as muscle
catabolism, anorexia, inflammation, growth failure, and
hypogonadism. To our knowledge, this is the first report
implicating systemic Zn redistribution and dyshomeostasis as
central causative mechanisms in cancer cachexia.
The APR plays an important role in cachexia, and it is
known to disrupt the carefully maintained Zn homeostasis
and to mediate the systemic redistribution of Zn. This
redistribution is mediated by Zn transporters that are
significantly upregulated by APR factors such as IL-6.
The primary purpose of muscle protein catabolism associ-
ated with APR seems to be the supply of amino acids for
the production of hepatic proteins deployed in the defense
response. We suggest that Zn accumulation into skeletal
muscle tissue may be associated with protein catabolism
and that this link should be further investigated.
Cancer cachexia is characterized not only by muscle
wasting, but also by anorexia, systemic inflammation,
pediatric growth failure, and hypogonadism. Zn homeo-
stasis is essential for the normal function of all these
processes and functional Zn deficiency compromises
them. We hypothesize that Zn is accumulated in certain
tissues and deprived from others resulting in severe
systemic Zn dyshomeostasis and that as a result, cachexia
may require completely new therapeutic approaches.
Skeletal muscle Zn levels may provide the first practical
and cost-effective diagnostic biomarker for cachexia, and
we urge research centers to measure the Zn levels in their
cachexic muscle biopsy samples.
The Zn–cachexia hypothesis has parsimonious explana-
tory power, but clearly the correlation and causality of Zn
dyshomeostasis in cancer cachexia need to be further
investigated. However, it is well established that Zn
metabolism is critical for normal health and function and
that systemic and chronic Zn dyshomeostasis has serious
pathophysiological implications.
Other cachexia symptoms, such as insulin resistance,
depression, and taste dysfunction are also associated with
Zn deficiency [140–142] and should be further explored in
light of the zinc-cachexia hypothesis. The possible role of
systemic Zn dyshomeostasis in other cachexia-inducing con-
ditions such as AIDS (originally known as ‘Slim Disease’),
chronic heart failure, chronic obstructive pulmonary disease,
chronic kidney disease, rheumatoid arthritis, severe injury,
chronic inflammation, and sepsis should also be investigated.
We propose that systemic Zn redistribution and dyshomeo-
stasis play a central and thus far unappreciated role in cancer
cachexia.
Acknowledgments The authors dedicate this work to the memory of
PirkkoandJormaGallen-Kallelawhomadeitscompletionpossible.Matti
and Pontus Siren have been supported in this work by the Paavo Nurmi
Foundation (Helsinki, Finland). All authors of this manuscript comply
with the guidelines of ethical authorship and publishing in the Journal of
Cachexia, Sarcopenia and Muscle [143].
Conflict of interest Siren PMA and Siren MJ are directors of
Bioneris Ab. There are no other conflicts of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which permits
any noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
1. Stephens NA, Skipworth RJ, Fearon KC. Cachexia, survival and
the acute phase response. Curr Opin Support Palliat Care.
2008;2:267–74.
2. von Haehling S, Lainscak M, Springer J, Anker SD.
Cardiac cachexia: a systematic overview. Pharmacol Ther.
2009;121:227–52.
3. Koehler F, Doehner W, Hoernig S, Witt C, Anker SD, John M.
Anorexia in chronic obstructive pulmonary disease—association
to cachexia and hormonal derangement. Int J Cardiol.
2007;119:83–9.
4. Cheung WW, Paik KH, Mak RH. Inflammation and cachexia in
chronic kidney disease. Pediatr Nephrol. 2010;25:711–24.
5. Delano MJ, Moldawer LL. The origins of cachexia in acute
and chronic inflammatory diseases. Nutr Clin Pract.
2006;21:68–81.
6. Tisdale MJ. The ubiquitin–proteasome pathway as a therapeutic
target for muscle wasting. J Support Oncol. 2005;3:209–17.
7. Kotler DP. Nutritional alterations associated with HIV infection.
J Acquir Immune Defic Syndr. 2000;25:S81–7.
8. Wray CJ, Mammen JM, Hasselgren PO. Catabolic response to
stress and potential benefits of nutrition support. Nutrition.
2002;18:971–7.
9. Evans WJ, Morley JE, Argilés J, Bales C, Baracos V,
Guttridge D, et al. Cachexia: a new definition. Clin Nutr.
2008;27:793–9.
10. Lainscak M, Filippatos GS, Gheorghiade M, Fonarow GC,
Anker SD. Cachexia: common, deadly, with an urgent need for
precise definition and new therapies. Am J Cardiol.
2008;101:8E–10E.
J Cachexia Sarcopenia Muscle (2010) 1:23–33 2911. Hambidge KM, Krebs NF. Zinc deficiency: a special challenge. J
Nutr. 2007;137:1101–5.
12. Maret W. Molecular aspects of human cellular zinc homeostasis:
redox control of zinc potentials and zinc signals. Biometals.
2009;22:149–57.
13. Takeda A, Tamano H, Enomoto S, Oku N. Zinc-65 imaging of
rat brain tumors. Cancer Res. 2001;61:5065–9.
1 4 .N e m o t oK ,K o n d oY ,H i m e n oS ,S u z u k iY ,H a r aS ,A k i m o t o
M, et al. Modulation of telomerase activity by zinc in human
prostatic and renal cancer cells. Biochem Pharmacol.
2000;59:401–5.
15. CiprianoC,TeseiS,MalavoltaM,GiacconiR,MutiE,CostarelliL,
et al. Accumulation of cells with short telomeres is associated with
impaired zinc homeostasis and inflammation in old hypertensive
participants. J Gerontol A Biol Sci Med Sci. 2009;64:745–51.
16. Murakami M, Hirano T. Intracellular zinc homeostasis and zinc
signaling. Cancer Sci. 2008;99:1515–22.
17. Memon AU, Kazi TG, Afridi HI, Jamali MK, Arain MB, Jalbani
N, et al. Evaluation of zinc status in whole blood and scalp hair
of female cancer patients. Clin Chim Acta. 2007;379:66–70.
18. Gupta SK, Singh SP, Shukla VK. Copper, zinc, and Cu/Zn ratio
in carcinoma of the gallbladder. J Surg Oncol. 2005;91:204–8.
19. Büntzel J, Bruns F, Glatzel M, Garayev A, Mücke R, Kisters K,
et al. Zinc concentrations in serum during head and neck cancer
progression. Anticancer Res. 2007;27:1941–3.
20. Kopański Z, Piekoszewski W, Habiniak J, Wojewoda T,
Wojewoda A, Schlegel-Zawadzka M, et al. The clinical
value of the determinations in the serum of zinc concentra-
tion in women with breast cancer. Folia Histochem
Cytobiol. 2001;39:84–6.
21. Mazdak H, Yazdekhasti F, Movahedian A, Mirkheshti N,
Shafieian M. The comparative study of serum iron, copper, and
zinc levels between bladder cancer patients and a control group.
Int Urol Nephrol. 2010;42:89–93.
22. Zuo XL, Chen JM, Zhou X, Li XZ, Mei GY. Levels of selenium,
zinc, copper, and antioxidant enzyme activity in patients with
leukemia. Biol Trace Elem Res. 2006;114:41–53.
23. Westin T, Ahlbom E, Johansson E, Sandström B, Karlberg I,
Edström S. Circulating levels of selenium and zinc in relation to
nutritional status in patients with head and neck cancer. Arch
Otolaryngol Head Neck Surg. 1989;115:1079–82.
24. Katz RL, Keen CL, Litt IF, Hurley LS, Kellams-Harrison KM,
Glader LJ. Zinc deficiency in anorexia nervosa. J Adolesc Health
Care. 1987;8:400–6.
25. Prasad AS, Bao B, Beck FW, Sarkar FH. Correction of
interleukin-2 gene expression by in vitro zinc addition to
mononuclear cells from zinc-deficient human subjects: a
specific test for zinc deficiency in humans. Transl Res.
2006;148:325–33.
26. Maret W, Sandstead HH. Zinc requirements and the risks and
benefits of zinc supplementation. J Trace Elem Med Biol.
2006;20:3–18.
27. King JC, Shames DM, Woodhouse LR. Zinc homeostasis in
humans. J Nutr. 2000;130:1360S–6S.
28. Igic PG, Lee E, Harper W, Roach KW. Toxic effects associated
with consumption of zinc. Mayo Clin Proc. 2002;77:713–6.
29. U.S. Department of Agriculture, Agricultural Research Service.
USDA Nutrient Database for Standard Reference, Release 14.
Available: http://www.nal.usda.gov/fnic/foodcomp/search/
30. Lu J, Stewart AJ, Sadler PJ, Pinheiro TJ, Blindauer CA.
Albumin as a zinc carrier: properties of its high-affinity zinc-
binding site. Biochem Soc Trans. 2008;36:1317–21.
31. Armstrong T, Walters E, Varshney S, Johnson CD. Deficiencies
of micronutrients, altered bowel function, and quality of life
during late follow-up after pancreaticoduodenectomy for malig-
nancy. Pancreatology. 2002;2:528–34.
32. Berg JM, Shi Y. The galvanization of biology: a growing
appreciation for the roles of zinc. Science. 1996;271:1081–5.
33. Gabay C, Kushner I. Acute-phase proteins and other systemic
responses to inflammation. N Engl J Med. 1999;340:448–54.
34. Falconer JS, Fearon KC, Ross JA, Elton R, Wigmore SJ, Garden
OJ, et al. Acute-phase protein response and survival duration of
patients with pancreatic cancer. Cancer. 1995;75:2077–82.
35. Liuzzi JP, Lichten LA, Rivera S, Blanchard RK, Aydemir TB,
Knutson MD, et al. Interleukin-6 regulates the zinc transporter
Zip14 in liver and contributes to the hypozincemia of the acute-
phase response. Proc Natl Acad Sci USA. 2005;102:6843–8.
36. Lundholm K, Ekman L, Edström S, Karlberg I, Jagenburg R,
Scherstén T. Protein synthesis in liver tissue under the influence
of a methylcholanthrene-induced sarcoma in mice. Cancer Res.
1979;39:4657–61.
37. Preston T, Slater C, McMillan DC, Falconer JS, Shenkin A,
Fearon KC. Fibrinogen synthesis is elevated in fasting cancer
patients with an acute phase response. J Nutr. 1998;128:1355–
60.
38. Moshage H. Cytokines and the hepatic acute phase response. J
Pathol. 1997;181:257–66.
39. Gaetke LM, McClain CJ, Talwalkar RT, Shedlofsky SI. Effects
of endotoxin on zinc metabolism in human volunteers. Am J
Physiol. 1997;272:E952–6.
40. Boosalis MG, Solem LD, McCall JT, Ahrenholz DH, McClain
CJ. Serum zinc response in thermal injury. J Am Coll Nutr.
1988;7:69–76.
41. Cousins RJ. Absorption, transport, and hepatic metabolism of
copper and zinc: special reference to metallothionein and
ceruloplasmin. Physiol Rev. 1985;65:238–309.
42. Selektor Y, Parker RB, Sun Y, Bhattacharya ZW, SK WKT.
Tissue 65Zinc translocation in a rat model of chronic aldoste-
ronism. J Cardiovasc Pharmacol. 2008;51:359–64.
43. Bibby DC, Grimble RF. Temperature and metabolic changes in
rats after various doses of tumour necrosis factor alpha. J
Physiol. 1989;410:367–80.
44. Sakata Y, Morimoto A, Long NC, Murakami N. Fever and
acute-phase response induced in rabbits by intravenous and
intracerebroventricular injection of interleukin-6. Cytokine.
1991;3:199–203.
45. Ling PR, Schwartz JH, Jeevanandam M, Gauldie J, Bistrian
BR. Metabolic changes in rats during a continuous infusion
of recombinant interleukin-1. Am J Physiol. 1996;270:E305–
12.
46. Farquharson MJ, Al-Ebraheem A, Geraki K, Leek R, Jubb A,
Harris AL. Zinc presence in invasive ductal carcinoma of the
breast and its correlation with oestrogen receptor status. Phys
Med Biol. 2009;54:4213–23.
47. Lichten LA, Cousins RJ. Mammalian zinc transporters: nutritional
and physiologic regulation. Annu Rev Nutr. 2009;29:153–76.
48. Larsson S, Karlberg I, Selin E, Daneryd P, Peterson HI. Trace
element changes in serum and skeletal muscle compared to tumour
tissue in sarcoma-bearing rats. In Vivo. 1987;1:131–40.
49. Russell ST, Siren PM, Siren MJ, Tisdale M. The role of zinc in
the anti-tumour and anti-cachectic activity of D-myo-inositol 1,
2, 6-triphosphate. Br J Cancer. 2010;102:833–6.
50. Claxson A, Morris C, Blake D, Sirén M, Halliwell B, Gustafsson
T, et al. The anti-inflammatory effects of D-myo-inositol-1.2.6-
trisphosphate (PP56) on animal models of inflammation. Agents
Actions. 1990;29:68–70.
51. Felemez M, Spiess B. Investigation of the ternary D-myo-
inositol 1, 2, 6 tris(phosphate)-spermine-Zn2+ system in solu-
tion. J Inorg Biochem. 2001;84:107–11.
52. Russell ST, Siren PM, Siren MJ, Tisdale M. Attenuation of skeletal
muscle atrophy in cancer cachexia by D-myo-inositol 1, 2, 6-
triphosphate. Cancer Chemother Pharmacol. 2009;64:517–27.
30 J Cachexia Sarcopenia Muscle (2010) 1:23–335 3 . M e iX ,L u oX ,X uS ,X uD ,Z h e n gY ,X uS ,e ta l .
Gastroprotective effects of a new zinc(II)-curcumin complex
against pylorus-ligature-induced gastric ulcer in rats. Chem Biol
Interact. 2009;181:316–21.
54. Siddiqui RA, Hassan S, Harvey KA, Rasool T, Das T, Mukerji P,
et al. Attenuation of proteolysis and muscle wasting by curcumin
c3 complex in MAC16 colon tumour-bearing mice. Br J Nutr.
2009;102:967–75.
55. Frank AS, Schauble MK, Preiss IL. Trace element profiles in
murine Lewis lung carcinoma by radioisotope-induced X-ray
fluorescence. Am J Pathol. 1986;122:421–32.
56. Busquets S, Fuster G, Ametller E, Olivan M, Figueras M,
Costelli P, et al. Resveratrol does not ameliorate muscle wasting
in different types of cancer cachexia models. Clin Nutr.
2007;26:239–44.
57. McCarthy DO, Graves E. Conjugated linoleic acid pre-
serves muscle mass in mice bearing the Lewis lung
carcinoma, but not the B16 melanoma. Res Nurs Health.
2006;29:98–104.
58. Markison S, Foster AC, Chen C, Brookhart GB, Hesse A,
Hoare SR, et al. The regulation of feeding and metabolic rate
and the prevention of murine cancer cachexia with a small-
molecule melanocortin-4 receptor antagonist. Endocrinology.
2005;146:2766–73.
59. Crawford AJ, Bhattacharya SK. Excessive intracellular zinc
accumulation in cardiac and skeletal muscles of dystrophic
hamsters. Exp Neurol. 1987;95:265–76.
60. Muñoz-Delgado E, Morote-García JC, Romero-Romero R,
López-García I, Hernández-Córdoba M. Determination of zinc
in tissues of normal and dystrophic mice using electrothermal
atomic absorption spectrometry and slurry sampling. Anal
Biochem. 2006;348:64–8.
61. Hersko A, Ciechanover A, Heller H, Haas AL, Rose IA. Proposed
role of ATO in protein breakdown: conjugation of protein with
multiple chains of the polypeptide of ATP-dependent proteolysis.
Proc Natl Acad Sci USA. 1980;77:1783–6.
62. Goldberg AL. Protein degradation and protection against mis-
folded or damaged proteins. Nature. 2003;426:895–9.
63. Mitch WE, Goldberg AL. Mechanisms of muscle wasting. The
role of the ubiquitin–proteasome pathway. N Engl J Med.
1996;335:1897–905.
64. Breen HB, Espat NJ. The ubiquitin–proteasome proteolysis
pathway: potential target for disease intervention. J Parenter
Enteral Nutr. 2004;28:272–7.
65. Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev.
2009;89:381–410.
66. Zamanian-Daryoush M, Mogensen TH, DiDonato JA, Williams
BR. NF-kappaB activation by double-stranded-RNA-activated
protein kinase (PKR) is mediated through NF-kappaB-
inducing kinase and IkappaB kinase. Mol Cell Biol.
2000;20:1278–90.
67. Eley HL, Tisdale MJ. Skeletal muscle atrophy, a link between
depression of protein synthesis and increase in degradation. J
Biol Chem. 2007;282:7087–97.
68. Siren RST, PM SMJ, Tisdale MJ. Mechanism of attenuation of
protein loss in murine C(2)C(12) myotubes by d-myo-inositol 1,
2, 6-triphosphate. Exp Cell Res. 2010;316:286–95.
69. Siddiqui R, Pandya D, Harvey K, Zaloga GP. Nutrition modulation
of cachexia/proteolysis. Nutr Clin Pract. 2006;21:155–67.
70. Sakkas GK, Schambelan M, Mulligan K. Can the use of creatine
supplementation attenuate muscle loss in cachexia and wasting?
Curr Opin Clin Nutr Metab Care. 2009;12:623–7.
71. Dröge W, Hack V, Breitkreutz R, Holm E, Shubinsky G,
Schmid E, et al. Role of cysteine and glutathione in signal
transduction, immunopathology and cachexia. Biofactors.
1998;8:97–102.
72. Argiles JM, López-Soriano FJ, Busquets S. Novel
approaches to the treatment of cachexia. Drug Discov Today.
2008;13:73–8.
73. Davis MP, Dreicer R, Walsh D, Lagman R, LeGrand SB.
Appetite and cancer-associated anorexia: a review. J Clin Oncol.
2004;22:1510–7.
74. Jatoi A, Loprinzi CL, Sloan JA, Klee GG, Windschitl HE.
Neuropeptide Y, leptin, and cholecystokinin 8 in patients with
advanced cancer and anorexia: a North Central Cancer Treatment
Group exploratory investigation. Cancer. 2001;92:629–33.
75. Levenson CW. Zinc regulation of food intake: new insights on
the role of neuropeptide Y. Nutr Rev. 2003;61:247–9.
76. Jing MY, Sun JY, Weng XY. Insights on zinc regulation of food
intake and macronutrient selection. Biol Trace Elem Res.
2007;115:187–94.
77. McClain CJ, Kasarkis Jr EJ, Allen JJ. Functional consequences
of zinc deficiency. Prog Food Nutr Sci. 1985;9:185–226.
78. Chesters JK, Quarterman J. Effects of zinc deficiency on food
intake and feeding patterns of rats. Br J Nutr. 1970;24:1061–9.
79. Shay NF, Mangian HF. Neurobiology of zinc-influenced eating
behavior. J Nutr. 2000;130:1493S–9S.
80. Bakan R, Birmingham CL, Aeberhardt L, Goldner EM. Dietary
zinc intake of vegetarian and nonvegetarian patients with
anorexia nervosa. Int J Eat Disord. 1993;13:229–33.
81. Dinsmore WW, Alderdice JT, McMaster D, Adams CE, Love
AH. Zinc absorption in anorexia nervosa. Lancet. 1985;1:1041–2.
82. Casper RC, Kirschner B, Sandstead HH, Jacob RA, Davis JM.
An evaluation of trace metals, vitamins, and taste function in
anorexia nervosa. Am J Clin Nutr. 1980;33:1801–8.
83. Humphries L, Vivian B, Stuart M, McClain CJ. Zinc deficiency
and eating disorders. J Clin Psychiatry. 1989;50:456–9.
84. Bryce-Smith D, Simpson R. Case of anorexia nervosa respond-
ing to zinc sulphate. Lancet. 1984;2:350.
85. Humphries L, McClain MP, Vivian B, Cunnup L, McClain CJ
(1990) Anorexia nervosa, zinc supplementation and weight gain.
In: Anderson, H (ed.) Biology of feast and famine: relevance to
eating disorders symposium on nutrition research. (abs.)
86. Safai-Kutti S. Oral zinc supplementation in anorexia nervosa.
Acta Psychiatr Scand Suppl. 1990;82:14–7.
87. Birmingham CL, Goldner EM, Bakan R. Controlled trial of zinc
supplementation in anorexia nervosa. Int J Eat Disord.
1994;15:251–5.
88. Castro J, Deulofeu R, Gila A, Puig J, Toro J. Persistence of
nutritional deficiencies after short-term weight recovery in
adolescents with anorexia nervosa. Int J Eat Disord.
2004;35:169–78.
89. Su JC, Birmingham CL. Zinc supplementation in the treatment
of anorexia nervosa. Eat Weight Disord. 2002;7:20–2.
90. Birmingham CL, Gritzner S. How does zinc supplementation
benefit anorexia nervosa? Eat Weight Disord. 2006;11:e109–11.
91. Casper RC, Kirschner B, Jacob RA. Zinc and copper status
in anorexia nervosa. [proceedings]. Psychopharmacol Bull.
1978;14:53–5.
92. Goel T, Sankhwar SN. Comparative study of zinc levels in
benign and malignant lesions of the prostate. Scand J Urol
Nephrol. 2006;40:108–12.
93. Davies IJ, Musa M, Dormandy TL. Measurements of plasma
zinc in malignant disease. J Clin Pathol. 1968;21:363–5.
94. Lindsey AM, Piper BF. Anorexia, serum zinc, and immunologic
response in small cell lung cancer patients receiving chemother-
apy and prophylactic cranial radiotherapy. Nutr Cancer.
1986;8:231–8.
95. Hadden JW. Immunodeficiency and cancer: prospects for
correction. Int Immunopharmacol. 2003;3:1061–71.
96. Simons JP, Schols AM, Buurman WA, Wouters EF. Weight loss
and low body cell mass in males with lung cancer: relationship
J Cachexia Sarcopenia Muscle (2010) 1:23–33 31with systemic inflammation, acute-phase response, resting
energy expenditure, and catabolic and anabolic hormones. Clin
Sci (Lond). 1999;97:215–23.
97. Fearon KC. Cancer cachexia: developing multimodal therapy for
a multidimensional problem. Eur J Cancer. 2008;44:1124–32.
98. McMillan DC. Systemic inflammation, nutritional status and
survival in patients with cancer. Curr Opin Clin Nutr Metab
Care. 2009;12:223–6.
99. Rink L, Haase H. Zinc homeostasis and immunity. Trends
Immunol. 2007;28:1–4.
100. Haase H, Rink L. The immune system and the impact of zinc
during aging. Immun Ageing. 2009;6:9.
101. Bao B, Prasad A, Beck FW, Suneja A, Sarkar F. Toxic effect
of zinc on NF-kappaB, IL-2, IL-2 receptor alpha, and TNF-
alpha in HUT-78 (Th(0)) cells. Toxicol Lett. 2006;166:222–
8.
102. Vasto S, Mocchegiani E, Malavolta M, Cuppari I, Listì F, Nuzzo
D, et al. Zinc and inflammatory/immune response in aging. Ann
NY Acad Sci. 2007;1100:111–22.
103. Cook-Mills JM, Fraker PJ. Functional capacity of the residual
lymphocytes from zinc-deficient adult mice. Br J Nutr.
1993;69:835–48.
104. Kahmann L, Uciechowski P, Warmuth S, Plümäkers B,
Gressner AM, Malavolta M, et al. Zinc supplementation in
the elderly reduces spontaneous inflammatory cytokine release
and restores T cell functions. Rejuvenation Res. 2008;11:227–
37.
105. Fraker PJ, King LE, Laakko T, Vollmer TL. The dynamic link
between the integrity of the immune system and zinc status. J
Nutr. 2000;130:1399S–406S.
106. Shankar AH, Prasad AS. Zinc and immune function: the
biological basis of altered resistance to infection. Am J Clin
Nutr. 1998;68:447S–63S.
107. Prasad AS. Zinc: role in immunity, oxidative stress and chronic
inflammation. Curr Opin Clin Nutr Metab Care. 2009;12:646–
52.
108. Dardenne M. Zinc and immune function. Eur J Clin Nutr.
2002;56:S20–3.
109. Haase H, Rink L. Functional significance of zinc-related
signalling pathways in immune cells. Annu Rev Nutr.
2009;29:133–52.
110. Meacham LR, Mason PW, Sullivan KM. Auxologic and
biochemical characterization of the three phases of growth
failure in pediatric patients with brain tumors. J Pediatr
Endocrinol Metab. 2004;17:711–7.
111. Andrassy RJ, Chwals WJ. Nutritional support of the pediatric
oncology patient. Nutrition. 1998;14:124–9.
112. DeWys WD. Pathophysiology of cancer cachexia: current
understanding and areas for future research. Cancer Res.
1982;42:721s–6s.
113. Tapiero H, Tew KD. Trace elements in human physiology and
pathology: zinc and metallothioneins. Biomed Pharmacother.
2003;57:399–411.
114. MacDonald RS. The role of zinc in growth and cell proliferation.
J Nutr. 2000;130:1500S–8S.
115. Raulin J. Etudes cliniques sur la vegetation. Ann Sci Nat Bot
Biol Veg. 1869;11:93.
116. Sommer AL, Lipman CB. Evidence on the indispensable nature
of zinc and boron for higher green plants. Plant Physiol.
1926;1:231–49.
117. Todd WR, Elvehjem CA, Hart EB. Zinc in the nutrition of the
rat. Am J Physiol. 1933;107:146–56.
118. Tucker HF, Salmon WD. Parakeratosis or zinc deficiency disease
in the pig. Proc Soc Exp Biol Med. 1955;88:613–6.
119. Ott EA, Smith WH, Stob M, Beeson WM. Zinc deficiency
syndrome in the young lamb. J Nutr. 1964;82:41–50.
120. Prasad AS, Miale Jr A, Farid Z, Sandstead HH, Schulert
AR, Darby WJ. Biochemical studies on dwarfism, hypo-
gonadism, and anemia. Arch Intern Med. 1963;111:407–
28.
121. Prasad AS. Clinical, endocrinological and biochemical
effects of zinc deficiency. Clin Endocrinol Metab.
1985;14:567–89.
122. Jameson S. Zinc nutrition and human pregnancy, in progress
in clinical and biological research, volume 129. In: Prasad
AS, Cavdar AO, Brewer GJ, Aggett PJ, editors. Zinc
deficiency in human subjects. New York: Alan R Liss;
1983. p. 63.
123. Wapnir P. Zinc deficiency, malnutrition and the gastrointestinal
tract. J Nutr. 2000;130:1388S–92S.
124. Díaz-Gómez NM, Doménech E, Barroso F, Castells S, Corta-
barria C, Jiménez A. The effect of zinc supplementation on linear
growth, body composition, and growth factors in preterm infants.
Pediatrics. 2003;111:1002–9.
125. Salgueiro MJ, Zubillaga MB, Lysionek AE, Caro RA, Weill R,
Boccio JR. The role of zinc in the growth and development of
children. Nutrition. 2002;18:510–9.
126. Nishi Y. Zinc and growth. J Am Coll Nutr. 1996;15:340–
4.
127. Iannotti LL, Zavaleta N, Leon Z, Shankar AH, Caulfield LE.
Maternal zinc supplementation and growth in Peruvian infants.
Am J Clin Nutr. 2008;88:154–60.
128. West UM, CE HJ, Deurenberg P, Hautvast JG. Zinc supplemen-
tation and stunted infants in Ethiopia: a randomised controlled
trial. Lancet. 2000;355:2021–6.
129. Cavdar AO, Arcasoy A, Cin S, Babacan E, Gözdasoglu S.
Geophagia in Turkey: iron and zinc deficiency, iron and zinc
absorption studies and response to treatment with zinc in
geophagia cases, in progress in clinical and biological research,
volume 129. In: Prasad AS, Cavdar AO, Brewer GJ, Aggett PJ,
editors. Zinc deficiency in human subjects. New York: Alan R
Liss; 1983. p. 71.
130. Strasser F, Palmer JL, Schover LR, Yusuf SW, Pisters K,
Vassilopoulou-Sellin R, et al. The impact of hypogonadism and
autonomic dysfunction on fatigue, emotional function, and
sexual desire in male patients with advanced cancer: a pilot
study. Cancer. 2006;107:2949–57.
131. Chlebowski RT, Heber D. Hypogonadism in male patients
with metastatic cancer prior to chemotherapy. Cancer Res.
1982;42:2495–8.
132. Prasad AS. Zinc deficiency in human subjects. Prog Clin Biol
Res. 1983;129:1–33.
133. McClain CJ, Gavaler JS, Van Thiel DH. Hypogonadism in the
zinc-deficient rat: localization of the functional abnormalities. J
Lab Clin Med. 1984;104:1007–15.
134. Grant JK, Minguell J, Taylor P, Weiss M. A possible role of zinc
in the metabolism of testosterone by the prostate gland. Biochem
J. 1971;125:21P.
135. Karaca Z, Tanriverdi F, Kurtoglu S, Tokalioglu S, Unluhizarci
K, Kelestimur F. Pubertal arrest due to Zn deficiency: the
effect of zinc supplementation. Hormones (Athens).
2007;6:71–4.
136. Hamdi SA, Nassif OI, Ardawi MS. Effect of marginal or severe
dietary zinc deficiency on testicular development and functions
of the rat. Arch Androl. 1997;38:243–53.
137. Martin GB, White CL, Markey CM, Blackberry MA.
Effects of dietary zinc deficiency on the reproductive
system of young male sheep: testicular growth and the
secretion of inhibin and testosterone. J Reprod Fertil.
1994;101:87–96.
138. Kaya O, Gokdemir K, Kilic M, Baltaci AK. Zinc supplementa-
tion in rats subjected to acute swimming exercise: its effect on
32 J Cachexia Sarcopenia Muscle (2010) 1:23–33testosterone levels and relation with lactate. Neuro Endocrinol
Lett. 2006;27:267–70.
139. Prasad AS, Mantzoros CS, Beck FW, Hess JW, Brewer GJ. Zinc
status and serum testosterone levels of healthy adults. Nutrition.
1996;12:344–8.
140. Haase H, Maret W. Protein tyrosine phosphatases as targets of
the combined insulinomimetic effects of zinc and oxidants.
Biometals. 2005;18:333–8.
141. Levenson CW. Zinc: the new antidepressant? Nutr Rev.
2006;64:39–42.
142. Heyneman CA. Zinc deficiency and taste disorders. Ann
Pharcother. 1996;30:186–7.
143. von Haehling S, Morley JE, Coats AJS, Anker SD (2010) Ethical
guidelines for authorship and publishing in the Journal of
Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia
Muscle 1. doi:10.1007/s13539-010-0003-5
J Cachexia Sarcopenia Muscle (2010) 1:23–33 33